XML 49 R37.htm IDEA: XBRL DOCUMENT v3.22.1
Common Stock and Stockholders' Equity (Tables)
 12 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Schedule of Shares of Common Stock Reserved for Future Issuance The Company had reserved shares of common stock for future issuance pursuant to equity plans as follows (in thousands):
 As of March 31,
 20222021
Common stock options outstanding1,663 2,718 
RSUs outstanding3,351 3,293 
PSUs outstanding320 112 
Available for future stock option, RSU, and PSU grants13,904 12,281 
Available for future employee stock purchase plan awards2,988 2,702 
22,226 21,106 
Schedule of Stock Option, RSU and PSU, and Time-Based Restricted Stock Activity
The following table summarizes the Company’s stock option, restricted stock unit (“RSU”), and performance unit (“PSU”) award activities for the fiscal year ended March 31, 2022 (in thousands, except exercise price, contractual term and fair value information):
 Options OutstandingRSUs OutstandingPSUs Outstanding
 Number of SharesWeighted-
Average
Exercise
Price		Weighted-Average Remaining Contractual Term (in years)Aggregate Intrinsic ValueNumber of
Shares		Weighted-
Average Grant
Date Fair Value		Weighted-
Average Remaining Contractual Term (in years)		Aggregate
Intrinsic
Value		Number of
Shares		Weighted-
Average Grant
Date Fair Value		Weighted-
Average Remaining Contractual Term (in years)		Aggregate
Intrinsic
Value
Outstanding—April 1, 20212,718 $50.55 6.2$48,064 3,293 $67.76 2.8$202,459 112 $99.05 2.0$6,884 
Granted (1)— — 2,710 69.94 241 82.89 
Exercised/vested(848)37.56 39,003 (1,472)67.32 (33)99.05 
Canceled/forfeited(207)70.77 (1,180)66.83 — 
Outstanding - March 31, 20221,663 $54.66 5.6$31,436 3,351 $70.04 2.6$224,096 320 $86.88 1.8$21,430 
Options vested and expected to vest - March 31, 20221,662 $54.65 5.6$31,436 
Options vested and exercisable - March 31, 20221,310 $50.66 5.0$30,233 
RSUs and PSUs expected to vest - March 31, 20223,173 $69.54 $212,235 305 $87.00 $20,370 
(1) The above table includes 241,398 performance unit awards and does not include any time-based restricted stock issued as consideration for an acquisition which are further detailed in the table below.
The following table summarizes the time-based restricted stock issued as consideration for an acquisition during the fiscal years ended March 31, 2022, 2021, and 2020:
Fiscal Years Ending March 31,
Number of Shares of Time-Based Restricted Stock Granted as Consideration for Acquisitions
2020
—
2021
736,469 (1)
2022
199,492 (2)
(1) These shares were issued in connection with the Pixie Labs acquisition, which included a holdback arrangement with certain employees of Pixie Labs. These shares are subject to the recipients’ continued service and will be recognized as stock-based compensation expense over the vesting periods, which range from 18 months to 37 months from the closing date of the acquisition.
(2) These shares were issued in connection with the CodeStream acquisition, which included a holdback arrangement with certain employees of CodeStream. These shares are subject to the recipients’ continued service and will be recognized as stock-based compensation expense over the vesting periods, which range from 18 months to 42 months from the closing date of the acquisition.
Schedule of Assumptions Used to Estimate Fair Value of Stock Options Granted and ESPP Shares to be Issued The assumptions used to estimate the fair value of stock options granted and ESPP shares to be issued during the fiscal years ended March 31, 2022, 2021, and 2020 were as follows:
Stock Options:   
 Fiscal Year Ended March 31,
 202220212020
Expected term (years)066
Expected volatility
0 - 0%
44 - 46%
41 - 42%
Risk-free interest rate
0.00 - 0.00%
0.34 - 0.76%
1.45 - 3.06%
Dividend yield———
ESPP:   
 Fiscal Year Ended March 31,
 202220212020
Expected term (years)0.50.50.5
Expected volatility
38 - 76%
55 - 76%
33 - 60%
Risk-free interest rate
0.05 - 0.72%
0.06 - 0.12%
1.56 - 1.86%
Dividend yield———
Schedule of Cost of Revenue, Research and Development, Sales and Marketing and General and Administrative Expenses Cost of revenue, research and development, sales and marketing, and general and administrative expenses were as follows (in thousands):
 Fiscal Year Ended March 31,
 202220212020
Cost of revenue$5,042 $5,939 $5,303 
Research and development48,355 40,964 31,703 
Sales and marketing48,986 54,695 43,548 
General and administrative (1)
50,656 33,545 18,982 
Total stock-based compensation expense (2)
$153,039 $135,143 $99,536 
(1) Includes $9.6 million acceleration of share-based payment expense for the fiscal year ended March 31, 2022, for one of the Company’s executives due to his departure at the end of June 2021.
(2) Includes $0.5 million expense for the fiscal year ended March 31, 2022, due to the restructuring activities commenced in the first quarter of fiscal 2022. Refer to Note 18. Restructuring for more information.